Microdosing Semaglutide for Weight Maintenance: Who It's For

You have reached your goal weight. The active weight loss phase is done, and now you are thinking about what comes next. If you have been on semaglutide, you have probably wondered: can you stay on it at a lower dose, or do you need to stop completely?

The answer is more nuanced than yes or no. Semaglutide microdosing, or staying on a significantly lower maintenance dose, is a strategy some providers use for people who want to maintain their results. It is not an FDA-approved use, there is no standardized protocol, and doses below the labeled maintenance doses are off-label with little trial evidence behind them. But it is an option worth discussing with your provider if you are interested in continuing medication at a lower dose.

What “semaglutide microdosing” actually means

Semaglutide microdosing does not have a formal definition in medical literature. When providers and patients talk about it, they mean staying on semaglutide at doses substantially lower than the ones used for active weight loss.

Start with the label. For brand-name semaglutide for weight management (Wegovy), the dose steps up from 0.25mg weekly to a usual maintenance dose of 2.4mg weekly, with 1.7mg as an alternative maintenance dose, and the current label allows some people to increase to a maximum of 7.2mg weekly.^[3] “Microdoses” used for maintenance are often much lower: 0.25mg or 0.5mg per week. Those doses are off-label for ongoing maintenance. When a provider uses one, the exact dose depends on your individual response, your prior treatment history, and how much appetite control you need to maintain your current weight.

The key point: a provider who chooses a lower dose is making that decision based on clinical judgment, not from a textbook protocol. It is personalized to your situation.

Why lower doses might work for maintenance

Semaglutide is a GLP-1 receptor agonist that amplifies the natural satiety signal your body produces after meals. The lower doses on the escalation schedule are active doses, not placebo, which is part of why some providers think a lower dose may be enough for some people at maintenance. That idea has not been well tested in trials.

Think of appetite signaling like a volume knob. At the labeled maintenance doses (1.7mg to 2.4mg per week), the appetite signal is turned way down, which supports active weight loss. At a lower dose (0.25mg to 0.5mg per week), the signal may be turned down enough to reduce the constant urge to eat, but not so aggressively that you feel completely suppressed.

For someone who has already lost weight and built new eating habits, that lower-volume appetite reduction may be enough to maintain stability with fewer side effects than a full dose. For others, it is not, and weight starts to come back.

What the STEP 4 trial showed

The strongest evidence on maintenance comes from the STEP trials, and it is evidence for staying on the full dose. The STEP 4 trial, published in JAMA in 2021^[1], enrolled adults who had completed 20 weeks of semaglutide 2.4mg (an average loss of 10.6%) and randomized them to continue 2.4mg or switch to placebo for the next 48 weeks.

The findings were striking: people switched to placebo regained an average of 6.9% of body weight, while those who stayed on 2.4mg lost a further 7.9% on average.^[1] A separate extension of the STEP 1 trial followed adults who stopped semaglutide after 68 weeks: within a year, they had regained about two-thirds of the weight they had lost.^[2] Neither trial tested a lower “microdose” for maintenance. Results vary, and trial results describe study participants, not what will happen to you.

This tells you something important about what semaglutide does. It is not just jumpstarting weight loss; it is actively managing appetite signals. When you stop the medication, that appetite regulation goes away, and for many people, the urge to eat returns to pre-treatment levels. The regain is not a sign of failure. It is a sign that the medication was doing a real job managing a biological process.

Why maintenance is different from stopping entirely

If you stop semaglutide completely, you are left with your baseline appetite signals. For many people who started on GLP-1 or semaglutide in the first place, those baseline signals are difficult to manage. The STEP 4 and STEP 1 extension data show that directly: significant weight regain within a year is common.

With a maintenance dose, you are not eliminating appetite regulation; you are keeping it in place. At a lower dose it is less aggressive than the active weight-loss dose, but it is still present.

The basic mechanism does not change when the dose goes from 2.4mg to 0.5mg. The GLP-1 receptors are still being activated, still reducing appetite, still slowing gastric emptying. You are just using a lower dose for a less aggressive effect, and whether that is enough for you is something only time and monitoring will show.

What microdosing looks like in practice

If your provider recommends a lower maintenance dose, here is what that might look like. This is an illustration, not a standard protocol:

You were on 2.4mg per week for active weight loss. Your provider discusses stepping down to a lower dose for maintenance, often in stages (for example, 1.7mg first, which is still a labeled maintenance dose) rather than all at once. Each step is held for a while, monitoring how you feel and how your weight behaves.

At a lower dose such as 0.5mg per week, you might find that your appetite is reduced but not suppressed. You feel normal hunger at meals, but you do not feel compelled to snack or think about food constantly throughout the day. Your weight may stay stable, or it may not.

The dose is adjusted based on your individual response. If you are losing weight when you want to maintain, a provider might go lower. If you are starting to experience hunger creep, your provider might suggest stepping back up or considering a different approach. For many people, the right answer turns out to be staying at a labeled maintenance dose.

This is clinical judgment, not protocol. Your provider makes decisions based on your specific situation: your response to medication, your eating habits, your goals, and your health history.

Semaglutide vs. tirzepatide for maintenance

Both medications are used in maintenance contexts, but they work differently and are not interchangeable.

Semaglutide is a GLP-1 receptor agonist. It has been in clinical use longer than tirzepatide, so there is more real-world experience with it at different doses, though very little trial data on doses below the labeled maintenance doses.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. Its doses are on a different scale, so the milligram numbers are not comparable to semaglutide. Some people switch to tirzepatide for maintenance, while others prefer to stay with semaglutide if they are doing well.

Your provider can help you decide what makes sense. If you used semaglutide during active treatment, people often continue with semaglutide for maintenance unless there is a clinical reason to switch. Read more: Microdosing Tirzepatide.

The role of compounded semaglutide in maintenance

Some telehealth programs prescribe compounded semaglutide, prepared by state-licensed compounding pharmacies, for maintenance. Compounded medications are not FDA-approved, the FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name semaglutide (Wegovy or Ozempic). They may differ in formulation, purity, and potency.

Programs that use compounded semaglutide sometimes point to dose flexibility as a reason, since a compounding pharmacy can prepare doses that do not match brand-name pen strengths. Ask which pharmacy prepares the medication, whether it is a 503A or 503B pharmacy, and how the dose is measured. Prices vary by program and dose; compare the total cost, including medication, dose changes, visits, labs, shipping, membership fees, and cancellation terms.

What to check before using semaglutide for maintenance

If you are at goal weight and thinking about a maintenance dose, the plan, and what it costs, depends on the provider and program you choose. Programs handle maintenance very differently, so ask before you change anything.

Who this tends to fit:

• People who have completed a period of active treatment and are at or near goal weight
• People who want to hold their results and are open to staying on some dose rather than stopping outright
• Whether medication remains appropriate for you is a clinical decision a licensed provider makes based on your history and any contraindications

What to ask any program you are considering:

• What maintenance dose would you suggest for me, and is it within the labeled maintenance doses or below them (off-label)? What evidence supports it?
• Is the medication an FDA-approved brand-name product or compounded? If compounded, which licensed pharmacy prepares it?
• Does the price change when my dose goes down? What does it include: medication, provider follow-ups, lab work, coaching, shipping, membership fees, cancellation terms?
• How often will a provider check in during maintenance, and what lab work, if any, is involved?
• What is the plan if my weight starts to come back?

How the process should work

At most telehealth programs, the process for a maintenance prescription should look something like this:

1. You complete the program’s health questionnaire, covering your health history, your prior experience with GLP-1 medications, your current weight, and your goals.
2. A licensed provider reviews your information and decides whether a maintenance dose is medically appropriate for you, and at what dose.
3. Depending on the program and your state, that review may include a phone or video visit. Some states require a live video visit before a first prescription can be written; if that applies where you live, the provider you choose will tell you.
4. If a prescription is written, it is filled by a licensed pharmacy, either a brand-name product or a compounded preparation, depending on what the provider prescribes.
5. The provider should follow up during maintenance to monitor your progress and adjust your dose if needed. Ask how often that happens before you sign up.

What happens if maintenance is not right for you

Microdosing is not the only path after reaching goal weight. Some people stop medication entirely and work to maintain through diet and exercise, though the trial data shows most people regain weight after stopping. Some people find that even a low dose is more than they want, or not necessary. Some people stay on a labeled maintenance dose if they continue to have strong appetite signals.

Your provider can discuss what makes sense for your specific situation. A lower maintenance dose is one option among several. The goal is to find what works for you long-term.

Transformation Health is relaunching as an independent GLP-1 guide with a free custom report that compares programs. Leave your email to be told when the report is available.

Key takeaways

• Semaglutide microdosing is not an FDA-approved use. Ongoing doses below the labeled maintenance doses (2.4mg usual, 1.7mg alternative) are off-label and have little trial evidence behind them.
• There is no official protocol. If a lower dose is used, the provider you choose sets it based on your response, goals, and health history.
• In STEP 4, people switched to placebo regained an average of 6.9% of body weight, while those who stayed on 2.4mg lost a further 7.9%. In the STEP 1 extension, people who stopped regained about two-thirds of the weight they had lost within a year. Results vary.
• Lower maintenance doses some providers use are often 0.25mg to 0.5mg per week, well below the labeled maintenance doses.
• Programs differ in what they prescribe, how they price maintenance, and how often they follow up. Compare the total cost and the plan before you commit.
• A licensed provider decides whether maintenance dosing is appropriate for you based on your individual health history and goals.

What to read next

Learn more about the full path after reaching goal weight by reading GLP-1 Microdosing and Maintenance. If you are thinking about stopping medication entirely, Stopping Weight Loss Medication: What Happens walks through the trial data and what to expect.

For more on what compounded semaglutide is and how it differs from brand-name products, see Is Compounded Semaglutide Safe? What the Regulatory Facts Tell You.

Citations

[1] Rubino D, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.” JAMA 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/33755728/

[2] Wilding JPH, et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.” Diabetes Obes Metab 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/

[3] Novo Nordisk. Wegovy (semaglutide) prescribing information, sections 2 and 3. Revised 06/2026 (NDA 215256, supplement 25). Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf